Screening for Fatty Liver Disease

Who Should Be Screened

The American Association for the Study of Liver Diseases recommends screening patients with diabetes, metabolic syndrome (≥2 metabolic risk factors), obesity, or persistently elevated liver enzymes using liver function tests and abdominal ultrasonography as the primary imaging modality 1, 2, 3
Patients with type 2 diabetes mellitus should be screened, as screening is cost-effective and should be performed regardless of liver enzyme levels, according to the American Diabetes Association 3, 4
Patients with persistently elevated AST or ALT should be screened, as NAFLD is the most common cause of unexplained liver enzyme elevation, as stated by the European Association for the Study of the Liver 1, 2, 3
Patients with ≥2 metabolic syndrome components, including central obesity, hypertension, elevated triglycerides, low HDL cholesterol, and elevated fasting glucose, should be screened, as recommended by the International Diabetes Federation 1, 2

The European Association for the Study of the Liver recommends obtaining a comprehensive history and performing tests to exclude other causes before diagnosing NAFLD, including essential exclusions such as alcohol use, viral hepatitis, drug-induced hepatitis, autoimmune liver diseases, and Wilson's disease 5, 6, 7
A baseline metabolic panel should include a complete blood count, comprehensive metabolic panel, lipid panel, and fasting glucose or HbA1c, as recommended by the American Association for the Study of Liver Diseases 1, 2, 4
Abdominal ultrasonography is the recommended first-line screening modality for detecting hepatic steatosis, with advantages including wide availability, cost-effectiveness, and high accuracy for moderate-to-severe steatosis, according to the American College of Gastroenterology 3, 8

The American Association for the Study of Liver Diseases recommends assessing for advanced fibrosis using non-invasive scores, such as the FIB-4 score, in patients with confirmed or suspected NAFLD, particularly high-risk individuals (age >50 years, diabetes, metabolic syndrome) 1, 2, 4
The FIB-4 score uses age, AST, ALT, and platelet count, and has the best diagnostic accuracy for advanced fibrosis among simple scores, as stated by the American Gastroenterological Association 4

Transient elastography with controlled attenuation parameter (CAP) simultaneously quantifies fat deposition and assesses fibrosis, and is useful for monitoring changes over time, according to the European Association for the Study of the Liver 3, 8
Magnetic resonance imaging (MRI) is superior to ultrasonography for detecting mild steatosis (<30% fat) and provides more accurate quantification of hepatic fat, as recommended by the American College of Radiology 5, 6, 7, 8

When fatty liver is detected, screen for associated conditions, such as metabolic syndrome components, type 2 diabetes, cardiovascular disease risk, and chronic kidney disease, as recommended by the American Heart Association 1, 2, 5, 6, 7
The American Diabetes Association recommends screening for type 2 diabetes using fasting glucose, HbA1c, or oral glucose tolerance test if indicated 5, 6, 7

Ultrasound has only 53-65% sensitivity for mild steatosis and frequently produces false positives, with 48-72% of patients with "mild" steatosis on ultrasound having negative confirmatory imaging 9, 10
83% of patients with negative ultrasound may still have histologic steatosis 11, 12

Nearly half of patients with mild steatosis by ultrasound have moderate steatosis on definitive testing 9, 10

In adults with obesity and unexplained liver enzyme elevation, a detailed clinical interview should quantify alcohol intake; consumption exceeding 21 standard drinks per week for men or 14 drinks per week for women meets the threshold for alcoholic liver disease rather than non‑alcoholic fatty liver disease. [13][14]

For patients with elevated transaminases, the work‑up must include serologic testing for hepatitis B and C, a medication review for drug‑induced injury, iron studies (serum ferritin and transferrin saturation) to screen for hereditary hemochromatosis, autoimmune markers (ANA, ASMA, immunoglobulins) for autoimmune hepatitis, alpha‑1‑antitrypsin level, and ceruloplasmin when age < 40 to rule out Wilson disease. [13][14]

A modestly raised serum ferritin level in an obese individual with liver enzyme abnormalities is frequently a feature of non‑alcoholic fatty liver disease and does not alone indicate iron overload; genetic testing for hemochromatosis should be pursued only when both ferritin and transferrin saturation are elevated. [13][14]